Lee Geun Taek, Srivastava Arnav, Kwon Young Suk, Kim Isaac Yi
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, and Division of Urology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey New Brunswick, NJ, USA.
Am J Clin Exp Urol. 2019 Apr 25;7(2):64-79. eCollection 2019.
Prostate cancer (PCa) is the most common non-cutaneous cancer among men and the second leading cause of male cancer deaths in the United States. With no effective cure for advanced disease, the survival rates of castration-resistant disease and metastatic disease remains poor. Treatment via hormonal manipulation, immunotherapy, and chemotherapy remain marginally effective, indicating the need for novel treatment strategies. Cytoreductive prostatectomy (CRP) has grown as a treatment modality for metastatic castration resistant prostate cancer (mCRPC) and an emerging body of literature has demonstrated its survival benefits. In this review, we hope to further explore immunologic changes after CRP and the resultant effects on oncologic outcomes. Conclusively, the data and technical considerations of CRS evolve, CRS may continue to expand treat various type of metastatic cancer. Still, there are little reports about immunological changed after CRP. However, based on technical improvement, CRP and combinational immunotherapy are developing treatments of metastatic disease.
前列腺癌（PCa）是男性中最常见的非皮肤癌，也是美国男性癌症死亡的第二大主要原因。由于晚期疾病没有有效的治愈方法，去势抵抗性疾病和转移性疾病的生存率仍然很低。通过激素操纵、免疫疗法和化疗进行的治疗仍然效果有限，这表明需要新的治疗策略。减瘤性前列腺切除术（CRP）已发展成为转移性去势抵抗性前列腺癌（mCRPC）的一种治疗方式，并且越来越多的文献表明了其生存益处。在本综述中，我们希望进一步探讨CRP后的免疫变化及其对肿瘤学结局的影响。总之，随着CRS数据和技术考量的不断发展，CRS可能会继续扩展以治疗各种类型的转移性癌症。然而，关于CRP后免疫变化的报道仍然很少。不过，基于技术改进，CRP和联合免疫疗法正在成为转移性疾病的治疗方法。
